Wells Fargo’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $321K | Sell |
189,729
-176,440
| -48% | -$773K | ﹤0.01% | 4395 |
|
|
2025
Q4 | $1.9M | Buy |
366,169
+4,700
| +1% | +$24.1K | ﹤0.01% | 3487 |
|
|
2025
Q3 | $1.89M | Sell |
361,469
-2,700
| -0.7% | -$14.1K | ﹤0.01% | 3348 |
|
|
2025
Q2 | $1.39M | Sell |
364,169
-28,363
| -7% | -$73.3K | ﹤0.01% | 3489 |
|
|
2025
Q1 | $2.26M | Sell |
392,532
-1,122
| -0.3% | -$6.63K | ﹤0.01% | 3079 |
|
|
2024
Q4 | $1.96M | Buy |
393,654
+7,348
| +2% | +$37.7K | ﹤0.01% | 3210 |
|
|
2024
Q3 | $2.08M | Sell |
386,306
-8,991
| -2% | -$42.8K | ﹤0.01% | 3017 |
|
|
2024
Q2 | $1.31M | Buy |
395,297
+7,993
| +2% | +$31.3K | ﹤0.01% | 3305 |
|
|
2024
Q1 | $1.27M | Buy |
387,304
+42,191
| +12% | +$139K | ﹤0.01% | 3295 |
|
|
2023
Q4 | $1.21M | Buy |
345,113
+1,841
| +0.5% | +$5.68K | ﹤0.01% | 3301 |
|
|
2023
Q3 | $2.29M | Buy |
343,272
+3,396
| +1% | +$25.2K | ﹤0.01% | 2701 |
|
|
2023
Q2 | $2.85M | Buy |
339,876
+68,033
| +25% | +$670K | ﹤0.01% | 2612 |
|
|
2023
Q1 | $2.7M | Sell |
271,843
-46,004
| -14% | -$325K | ﹤0.01% | 2624 |
|
|
2022
Q4 | $2.21M | Buy |
317,847
+7,441
| +2% | +$42.5K | ﹤0.01% | 2714 |
|
|
2022
Q3 | $1.66M | Sell |
310,406
-20,951
| -6% | -$126K | ﹤0.01% | 2878 |
|
|
2022
Q2 | $1.32M | Buy |
331,357
+820
| +0.2% | +$2.82K | ﹤0.01% | 3101 |
|
|
2022
Q1 | $1.47M | Buy |
330,537
+93,897
| +40% | +$374K | ﹤0.01% | 3566 |
|
|
2021
Q4 | $947K | Sell |
236,640
-22,821
| -9% | -$174K | ﹤0.01% | 4159 |
|
|
2021
Q3 | $2.28M | Buy |
259,461
+118,633
| +84% | +$1.09M | ﹤0.01% | 3549 |
|
|
2021
Q2 | $1.59M | Buy |
140,828
+66,152
| +89% | +$795K | ﹤0.01% | 3886 |
|
|
2021
Q1 | $887K | Buy |
74,676
+67,423
| +930% | +$776K | ﹤0.01% | 4329 |
|
|
2020
Q4 | $50K | Buy |
7,253
+7,016
| +2,960% | +$49.3K | ﹤0.01% | 5583 |
|
|
2020
Q3 | $2K | Sell |
237
-278
| -54% | -$1.8K | ﹤0.01% | 6117 |
|
|
2020
Q2 | $2K | Sell |
515
-16,236
| -97% | -$59.3K | ﹤0.01% | 6080 |
|
|
2020
Q1 | $41K | Sell |
16,751
-1,039
| -6% | -$4.67K | ﹤0.01% | 5407 |
|
|
2019
Q4 | $103K | Sell |
17,790
-30,721
| -63% | -$177K | ﹤0.01% | 5282 |
|
|
2019
Q3 | $255K | Buy |
48,511
+5,775
| +14% | +$31.1K | ﹤0.01% | 4814 |
|
|
2019
Q2 | $257K | Buy |
42,736
+328
| +0.8% | +$2.47K | ﹤0.01% | 4826 |
|
|
2019
Q1 | $383K | Sell |
42,408
-2,492
| -6% | -$21.2K | ﹤0.01% | 4484 |
|
|
2018
Q4 | $372K | Buy |
44,900
+27,355
| +156% | +$280K | ﹤0.01% | 4519 |
|
|
2018
Q3 | $243K | Buy |
17,545
+707
| +4% | +$5.74K | ﹤0.01% | 4896 |
|
|
2018
Q2 | $133K | Buy |
16,838
+2,307
| +16% | +$18.4K | ﹤0.01% | 5233 |
|
|
2018
Q1 | $109K | Buy |
14,531
+991
| +7% | +$7.52K | ﹤0.01% | 5266 |
|
|
2017
Q4 | $92K | Buy |
+13,540
| New | +$89.2K | ﹤0.01% | 5347 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Wells Fargo's ALDX Position: Q1 2026 in Review
Wells Fargo reduced its Aldeyra Therapeutics (ALDX) stake by 48% in Q1 2026, selling an estimated $773K and leaving 189,729 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #4395.
Wells Fargo first reported a position in ALDX in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.85M in Q2 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Wells Fargo held 189,729 shares of Aldeyra Therapeutics worth $321K as of Q1 2026.
- Wells Fargo sold 176,440 Aldeyra Therapeutics shares in Q1 2026, an estimated $773K.
- Aldeyra Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4395 holding.
- Wells Fargo first reported a position in Aldeyra Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Wells Fargo's Aldeyra Therapeutics position peaked at $2.85M in Q2 2023.
- 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.